MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 51,873 Shares

Key Points

• MoonLake CEO Da Silva Jorge Santos sold 51,873 shares on April 13 at an average of $18.23 for about $945,645 (after selling 98,127 shares on April 10), leaving him with 2,924,893 shares — a 1.74% reduction in his stake valued at roughly $53.3M.
• Shares traded up ~1.9% to $18.78 on Tuesday with below-average volume; MoonLake has a market cap near $1.35B, a 52-week range of $5.95–$62.75, and a consensus analyst rating of Hold with a $23.08 target (9 Buys, 4 Holds, 3 Sells).

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 51,873 shares of the company's stock in a transaction on Monday, April 13th. The shares were sold at an average price of $18.23, for a total value of $945,644.79. Following the completion of the transaction, the chief executive officer directly owned 2,924,893 shares in the company, valued at approximately $53,320,799.39. This trade represents a 1.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Da Silva Jorge Santos also recently made the following trade(s):

• On Friday, April 10th, Da Silva Jorge Santos sold 98,127 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $18.41, for a total value of $1,806,518.07.

MoonLake Immunotherapeutics Trading Up 1.9%

Shares of NASDAQ:MLTX traded up $0.35 during midday trading on Tuesday, reaching $18.78. 1,079,418 shares of the company's stock were exchanged, compared to its average volume of 1,931,781. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -5.34 and a beta of 1.19. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The firm's 50 day simple moving average is $17.22 and its two-hundred day simple moving average is $14.61. The company has a debt-to-equity ratio of 0.24, a current ratio of 9.27 and a quick ratio of 9.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, meeting analysts' consensus estimates of ($0.92). During the same quarter last year, the firm posted ($0.72) earnings per share. As a group, sell-side analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MLTX has been the topic of several recent analyst reports. BTIG Research restated a "buy" rating and issued a $30.00 price objective on shares of MoonLake Immunotherapeutics in a report on Monday, March 30th. Needham & Company LLC boosted their target price on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the company a "buy" rating in a research report on Monday, February 23rd. Royal Bank Of Canada upped their price target on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a "sector perform" rating in a research note on Monday, March 2nd. Oppenheimer raised their price target on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 24th. Finally, Rothschild & Co Redburn raised MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $12.00 to $40.00 in a research note on Thursday, March 19th. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.08.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of hedge funds have recently bought and sold shares of MLTX. Kestra Advisory Services LLC acquired a new stake in MoonLake Immunotherapeutics in the 4th quarter valued at about $26,000. FNY Investment Advisers LLC acquired a new position in shares of MoonLake Immunotherapeutics during the third quarter worth about $28,000. Bank of America Corp DE increased its stake in shares of MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company's stock worth $32,000 after buying an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of MoonLake Immunotherapeutics by 115.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company's stock worth $42,000 after buying an additional 3,166 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company's stock valued at $45,000 after acquiring an additional 1,069 shares in the last quarter. Institutional investors and hedge funds own 93.85% of the company's stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.